Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semuloparin for VTE Prevention in Total Hip Replacement Surgery
NCT00697099Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jun 2008
- Primary completion
- Jun 2009
- Countries
- 30
01
Overview
Phase 3, randomised, double-blind trial of semuloparin in venous thromboembolism (VTE), sponsored by Sanofi. Primary endpoint: Venous Thromboembolism Event or Death From Any Cause at 10 days. Started Jun 2008; status: completed.
02
Drugs
semuloparin
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT00697099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00697099.